x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:10:52

Breakwater, Ensartinib, & SC Nivo

OncoPharm ·

2025/01/09

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

en

00:13:14

The Accelerated Approval Pathway

OncoPharm ·

2025/01/02

Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer.Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5

en

00:18:03

2024 New Drug Review

OncoPharm ·

2024/12/19

Looking back at new approvals from 2024 - what to keep, re-gift, or return?And yes, as soon as this was recorded 2 new drugs were approved.

en

00:17:05

A Feast Of Updates

OncoPharm ·

2024/12/12

Lots of recent clinical trial updates to discuss:AQUILA: Daratumumab for high-risk smoldering multiple myeloma Checkmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancer DESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBC ARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastric/GEJ cancer HELEN-006: Neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab vs. TCHP in breast cancer SONIA: finally published!

en

00:12:45

Zenocutuzumab

OncoPharm ·

2024/12/05

A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.

en

00:14:52

Revumenib

OncoPharm ·

2024/11/21

The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias.Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265

en

00:09:52

Anthracycline Use In Breast Cancer

OncoPharm ·

2024/11/14

A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191

en

00:09:18

SWISH

OncoPharm ·

2024/11/07

Reviewing the data to support use of dexamethasone solution mouthwash for PIK3/AKT/mTOR inhibitor-induced stomatitis, caused by drugs like everolimus, alpelisib, capivasertib, & inavolisib.SWISH: https://doi.org/10.1016/s1470-2045(17)30109-2 Alliance MIST Trial: https://doi.org/10.1053/j.seminoncol.2023.01.001

en

00:19:30

Zolbetuximab

OncoPharm ·

2024/10/31

The first Cldn 18.2 targeting monoclonal antibody has been improved. Let's talk about it!

en

00:22:49

S1826 & INTERLACE

OncoPharm ·

2024/10/24

Discussing two excellent articles from earlier this month.S1826: N-AVD vs. Bv-AVD (DOI: 10.1056/NEJMoa2405888) & INTERLACE: induction chemo prior to concurrent cisplatin/RT in locally advanced cervical cancer (DOI: https://doi.org/10.1016/S0140-6736(24)01438-7)

en

00:16:42

Inavolisib

OncoPharm ·

2024/10/17

A new PIK3Ca inhibitor is approved for breast cancer.

en

00:13:48

Autumnal (2024) AML Updates

OncoPharm ·

2024/10/10

Reviewing 3 recent AML publicationsDouble-Dauno (90 mg/m2 vs. 60 mg/m2): https://doi.org/10.1200/JCO.24.00235 AML60+ Risk Stratification: https://doi.org/10.1200/JCO.23.02631 Decitabine-Ven as bridge to Allo HSCT: https://doi.org/10.1016/S2352-3026(24)00241-2

en

00:10:03

MSI-High Rectal Cancer Treatment

OncoPharm ·

2024/10/03

MSI-high/MMRd rectal cancer treatment guidelines are being re-written. A brief synopsis of why treatment guidelines are changing so quickly in this space.Also, listeners helped out in explaining the ribociclib storage & stability change. Hint: https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2

en

00:16:39

NATALEE + a slew of FDA updates

OncoPharm ·

2024/09/26

FDA has been busy the last week approving:-ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement -osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC -amivantamab + chemotherapy following progression on osimertinib (Mariposa-2) -a subcutaneous formulation of atezolizumab -isatuximab + VRD for multiple myeloma -pembrolizumab + chemotherapy for metastatic pleural mesothelioma

en

00:22:17

ESMO 2024

OncoPharm ·

2024/09/19

Recapping just some of the notable data coming out of ESMO 2024:-Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC) -AMBASSADOR (adjuvant pembrolizumab in bladder cancer) -NIAGRA (perioperative durvalumab in bladder cancer) -ADRIATIC (discussed on ASCO recap Pod, but publication now available) -LEANOX (impact of lean body mass adjustment on oxaliplatin dose)

en

00:17:00

Doxorubicin + Trabectedin

OncoPharm ·

2024/09/05

LMS04 final OS results are published for doxorubicin + trabectedin in Leiomyosarcoma. Plus, a natural experiment of what happens in small cell lung cancer during an IV etoposide shortage. Finally, a nice paper provides some examples of how oncology pharmacists can bridge the care gap between oncology and primary care.LMS04: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2403394 IV etoposide shortage: https://doi.org/10.1200/OP.24.00394 Primary care - oncology pharmacy collaboration:

en

00:22:48

Chapter 1. Doses Matter

OncoPharm ·

2024/08/29

This is chapter 1 of a keynote address from summer 2024 on putting together the pieces of oncology pharmacy - with an emphasis on how our knowledge of drug dosing changes with time.Video/slides available at YouTube: https://youtu.be/1Oae8AV5Af4

en

00:19:31

Cross-Trial Comparison Don'ts

OncoPharm ·

2024/08/22

We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.

en

00:14:17

Olanzapine For MEC

OncoPharm ·

2024/08/15

A mixed bag of Phase III results for using olanzapine with moderately emegotenic chemotherapy (MEC).Inui, et al: https://doi.org/10.1200/JCO.24.00278 Ostwal, et al: doi:10.1001/jamanetworkopen.2024.26076

en

00:12:29

Afamitresgene Autoleucel & Vorasidenib

OncoPharm ·

2024/08/08

A new cellular therapy is approved for synovial sarcoma and the anticipated approval has occurred for the dual IDH1/IDH2 inhibitor, vorasidenib.

en

421 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter